Professor Ian Feavers
Ian Feavers is an emeritus senior research associate with Martin Maiden’s group. He retired as Head of Bacteriology at the National Institute for Biological Standards and Control (NIBSC, a Centre of the MHRA) in the UK in September 2019. His research interests include vaccine development and the standardisation of assays. For many years he has collaborated with the group on the antigenic diversity and population biology of the meningococcus, and collaborated in the development of the MLST approach to bacterial genotyping. He is currently a member of the WHO’s Expert Committee on Biological Standardisation.
Bidmos,F.A., Chan,H., Praekelt,U., Tauseef,I., Ali,Y.M., Kaczmarski,E.B., Feavers,I. and Bayliss,C.D. (2015) Investigation into the Antigenic Properties and Contributions to Growth in Blood of the Meningococcal Haemoglobin Receptors, HpuAB and HmbR. PLoS One 10: e0133855
Sanders,H., Norheim,G., Chan,H., Dold,C., Vipond,C., Derrick,J.P., Pollard,A.J., Maiden,M.C. and Feavers,I.M. (2015) FetA Antibodies Induced by an Outer Membrane Vesicle Vaccine Derived from a Serogroup B Meningococcal Isolate with Constitutive FetA Expression. PLoS One 10: e0140345
Norheim,G., Sanders,H., Mellesdal,J.W., Sundfor,I., Chan,H., Brehony,C., Vipond,C., Dold,C., Care,R., Saleem,M., Maiden,M.C., Derrick,J.P., Feavers,I. and Pollard,A.J. (2015) An OMV Vaccine Derived from a Capsular Group B Meningococcus with Constitutive FetA Expression: Preclinical Evaluation of Immunogenicity and Toxicity. PLoS One 10: e0134353
Marsay,L., Dold,C., Green,C.A., Rollier,C.S., Norheim,G., Sadarangani,M., Shanyinde,M., Brehony,C., Thompson,A.J., Sanders,H., Chan,H., Haworth,K., Derrick,J.P., Feavers,I.M., Maiden,M.C. and Pollard,A.J. (2015) A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial. J. Infect. 71; 326-337
Maharjan,S., Saleem,M., Feavers,I.M., Wheeler,J.X., Care,R. and Derrick,J.P. (2015) Dissection of the function of the RmpM periplasmic protein from Neisseria meningitidis. Microbiology 162: 364-375.
Vipond,C., Findlay,L., Feavers,I. and Care,R. (2016) Limitations of the rabbit pyrogen test for assessing meningococcal OMV based vaccines. ALTEX. 33: 47-53
Wetzler, L.M., Feavers, I.M., Gray-Owen, S.D., Jerse, A.E., Rice, P.A. and Deal, C.D. (2016) Summary and Recommendations from the National Institute of Allergy and Infectious Diseases (NIAID) Workshop "Gonorrhea Vaccines: the Way Forward". Clin.Vaccine Immunol. 23: 656-663
Feavers, I.M. and Maiden, M.C.J. (2017) Recent Progress in the Prevention of Serogroup B Meningococcal Disease. Clin.Vaccine Immunol. 24: e00566-16
Bryan, P., Seabroke, S., Wong, J., Donegan, K., Webb, E., Goldsmith, C., Vipond, C. and Feavers, I. (2018) Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study. The Lancet: Child and Adolescent Health. 2(6): 395-403
Markey, K., C. Asokanathan, and I. Feavers (2019) Assays for Determining Pertussis Toxin Activity in Acellular Pertussis Vaccines. Toxins (Basel). 11(7).